HK1135043A1 - Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area - Google Patents

Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area

Info

Publication number
HK1135043A1
HK1135043A1 HK10103574.6A HK10103574A HK1135043A1 HK 1135043 A1 HK1135043 A1 HK 1135043A1 HK 10103574 A HK10103574 A HK 10103574A HK 1135043 A1 HK1135043 A1 HK 1135043A1
Authority
HK
Hong Kong
Prior art keywords
liquid
instillative
inhalative
active substance
substance carrier
Prior art date
Application number
HK10103574.6A
Other languages
English (en)
Inventor
Hasso Meinert
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of HK1135043A1 publication Critical patent/HK1135043A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK10103574.6A 2008-04-18 2010-04-13 Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area HK1135043A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08007640A EP2110126B9 (de) 2008-04-18 2008-04-18 Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Publications (1)

Publication Number Publication Date
HK1135043A1 true HK1135043A1 (en) 2010-05-28

Family

ID=39708796

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103574.6A HK1135043A1 (en) 2008-04-18 2010-04-13 Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area

Country Status (15)

Country Link
US (1) US8986738B2 (xx)
EP (1) EP2110126B9 (xx)
JP (1) JP4990929B2 (xx)
CN (1) CN101559229B (xx)
AT (1) ATE532505T1 (xx)
AU (1) AU2009201137A1 (xx)
BR (1) BRPI0900767A2 (xx)
CA (1) CA2662943A1 (xx)
DK (1) DK2110126T3 (xx)
ES (1) ES2377152T3 (xx)
HK (1) HK1135043A1 (xx)
MX (1) MX2009003812A (xx)
PL (1) PL2110126T3 (xx)
PT (1) PT2110126E (xx)
TW (1) TWI417108B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2661280T3 (en) 2011-01-04 2019-03-04 Novaliq Gmbh O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
CN103596554A (zh) 2011-05-25 2014-02-19 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
PL2806886T3 (pl) * 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
AU2013251865B2 (en) * 2012-04-23 2017-02-16 Chiesi Farmaceutici S.P.A. Method and system for the administration of a pulmonary surfactant by atomization
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
CN106511322B (zh) 2012-09-12 2021-09-17 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
ES2682064T3 (es) 2012-09-12 2018-09-18 Novaliq Gmbh Composiciones para el lavado de ojos
MX370207B (es) * 2013-07-23 2019-12-05 Novaliq Gmbh Composiciones estabilizadas de anticuerpos.
US10925889B2 (en) * 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11648261B2 (en) * 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
PL3355990T3 (pl) 2015-09-30 2019-11-29 Novaliq Gmbh Semifluorowane związki oraz ich kompozycje
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
PL3856128T3 (pl) 2018-09-27 2023-10-16 Dermaliq Therapeutics, Inc. Formulacja filtra przeciwsłonecznego do stosowania miejscowego
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5869539A (en) 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
EP1740189B1 (en) 2004-04-19 2012-06-13 Centre National De La Recherche Scientifique -Cnrs- Lung surfactant supplements
DE102005055811A1 (de) * 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen

Also Published As

Publication number Publication date
EP2110126B9 (de) 2012-09-19
TW200950809A (en) 2009-12-16
EP2110126B1 (de) 2011-11-09
EP2110126A1 (de) 2009-10-21
ES2377152T3 (es) 2012-03-22
AU2009201137A1 (en) 2009-11-05
US8986738B2 (en) 2015-03-24
ES2377152T9 (es) 2013-02-18
CN101559229B (zh) 2013-07-31
CA2662943A1 (en) 2009-10-18
CN101559229A (zh) 2009-10-21
JP2009256353A (ja) 2009-11-05
PT2110126E (pt) 2012-02-20
MX2009003812A (es) 2009-10-19
PL2110126T3 (pl) 2012-04-30
US20100008996A1 (en) 2010-01-14
DK2110126T3 (da) 2012-02-27
TWI417108B (zh) 2013-12-01
JP4990929B2 (ja) 2012-08-01
BRPI0900767A2 (pt) 2010-12-28
ATE532505T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
HK1135043A1 (en) Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area
Dahmani et al. Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation
JP5271918B2 (ja) メタボリック症候群治療用の新規組成物
Wang et al. S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway
Xiao et al. Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
Shigemura et al. Early major neurologic complications after lung transplantation: incidence, risk factors, and outcome
AU2020286987A1 (en) Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
ATE527976T1 (de) Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes
BR112012025047A2 (pt) formulações líquidas estabilizadas
DE602007010807D1 (de) Vorrichtung für kombinierte behandlung
AR070842A1 (es) Regimen de dosificacion para un agonista de receptor selectivo de s1p1
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
WO2009097443A3 (en) Liquid formulations of compounds active at sulfonylurea receptors
CA2837341A1 (en) Method of determining vasoreactivity using inhaled nitric oxide
JP2015516378A5 (xx)
JP2023510661A (ja) 窒素酸化物を生成するための方法及び組成物、並びにそれらの使用
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
AU2021259360A1 (en) Nitric oxide or nitric oxide releasing compositions for use in treating SARS-CoV and SARS-CoV-2
JPWO2010103843A1 (ja) 鎮痛・抗炎症剤含有外用剤
ES2542177T3 (es) Uso de osmolitos obtenidos de bacterias extremófilas para la fabricación de medicamentos inhalables para la prevención y el tratamiento de enfermedades pulmonares y cardiovasculares, así como un dispositivo de inhalación que contiene osmolitos como componentes activos
AR085059A1 (es) Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
Taksande et al. Agmatine reverses ethanol consumption in rats: evidences for an interaction with imidazoline receptors
Kihara et al. Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170420